BPA Call 36C25525A0007-36C25526N0057
- Exact Sciences Corporation received a $3,453.96 task order award on March 16, 2026, from Veterans Integrated Service Network 15 (VISN 15) for Oncotype DX testing services at the Leavenworth Department of Veterans Affairs Medical Center. This firm fixed-price delivery order falls under a blanket purchase agreement established on March 16, 2025, with a total ceiling value of $1,071,290.72 through March 15, 2027, which supports oncology diagnostic testing across seven VA medical facilities in the...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, was awarded a task order valued at $3,116 under a Blanket Purchase Agreement (BPA) call for Oncotype DX Testing Services by the Department of Veterans Affairs' Veterans Integrated Service Network 15 (VISN 15). The award, issued on March 16, 2026, with an ultimate completion date of March 15, 2027, is structured as a firm fixed-price contract with no set-aside designation. Performance will take place in Marion,...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, was awarded a delivery order on October 1, 2022, valued at $203,932.36 for Oncotype DX testing services to support the Department of Veterans Affairs' Veterans Integrated Service Network 7 (VISN 7). The contract, which will be completed by July 31, 2027, operates under a firm fixed-price arrangement with no set-aside designation, enabling VISN 7 to procure specialized genomic testing services at a competitive...
- Exact Sciences Corporation, operating through its Exact Sciences Laboratories, LLC division, was awarded a $24,258.80 firm fixed-price task order by Veterans Integrated Service Network 15 on March 16, 2026, in support of Oncotype DX testing services at the St. Louis Veterans Affairs Medical Center. This task order was issued under a larger blanket purchase agreement established on March 16, 2025, with a $1.07M ceiling value through March 15, 2027, which provides a framework for oncology...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, was awarded a task order under a Blanket Purchase Agreement (BPA) for Oncotype DX testing services by Veterans Integrated Service Network 15 (VISN 15), a component of the Department of Veterans Affairs. This firm fixed-price contract, awarded on March 16, 2026, carries a ceiling value of $31,328.88 with an ultimate completion date of March 15, 2027. The contract was issued without a set-aside designation,...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, has been awarded a Firm Fixed Price task order under the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule Blanket Purchase Agreement with the Department of Veterans Affairs Veterans Integrated Service Network 15. The contract, valued at $10,442.96, was awarded on March 16, 2026, with an ultimate completion date of March 15, 2027, and will be performed in Kansas City, MO. This...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, was awarded a delivery order valued at $20,385.80 by Veterans Integrated Service Network 16 (VISN 16) on October 1, 2024, for Oncotype DX Breast Assay testing services. This firm fixed-price delivery order represents a task order call against the Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule, under which Exact Sciences holds multiple blanket purchase agreements with the...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, was awarded a delivery order valued at $594,081.12 for Oncotype gene expression breast cancer testing services by the Department of Veterans Affairs' Veterans Integrated Service Network 8 (VISN 8). The contract, awarded on May 15, 2022, operates under a firm fixed-price structure with an ultimate completion date of May 14, 2027, and will be performed in Tampa, Florida. This delivery order was issued without a...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, has been awarded the execution of Option Year 1 for Oncotype DX testing services to the Department of Veterans Affairs Veterans Integrated Service Network 15. This firm fixed-price Blanket Purchase Agreement (BPA) call, issued without a set-aside designation, carries a ceiling value of $17,769.92 and is scheduled for completion by March 15, 2027. The award was made on March 16, 2026, under the Medical Laboratory...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, received a $52.2K firm fixed-price Blanket Purchase Agreement (BPA) call from Veterans Integrated Service Network 17 (VISN 17), a Veterans Affairs civilian agency component, for Oncotype DX gene expression profiling services. The contract award was issued on June 5, 2026, with an ultimate completion date of June 4, 2027, and was performed at the contractor's facility in Temple, Texas. This award was not issued...
- Medical Laboratory Testing and Analysis Services (FSS-621-II)Master GSA Schedule
- V797D70053-36C25525A0007Blanket Purchase Agreement
- 36C25525A0007-36C25526N0057BPA Call
Exact Sciences Corporation, operating through its Exact Sciences Laboratories, LLC division, received a task order award valued at $3,453.96 from Veterans Integrated Service Network 15 on March 16, 2026, for Oncotype DX testing services supporting the Topeka Veterans Affairs Medical Center. This firm fixed-price delivery order is issued under a broader $1,071,290.72 blanket purchase agreement established between VISN 15 and Exact Sciences on March 16, 2025, which provides a framework for oncology diagnostic testing across seven VA medical facilities in the central United States through March 15, 2027. The contract does not utilize a set-aside designation and operates under the Medical Laboratory Testing and Analysis Services (FSS-621-II) General Services Administration schedule, reflecting Exact Sciences' competitive positioning as a specialized provider of proprietary cancer diagnostic assays. The award supports the Department of Veterans Affairs' oncology programs by delivering Oncotype DX gene expression profiling assays, which analyze mRNA expression in cancer tumor tissue to assess recurrence risk and treatment responsiveness. Exact Sciences has established itself as a leading federal provider of cancer diagnostic testing, holding multiple indefinite delivery vehicles and blanket purchase agreements across numerous Veterans Integrated Service Networks, the Defense Health Agency, and Department of Defense medical systems, with individual contract values ranging from approximately $3,000 to $2.9 million. The company's sustained federal presence reflects continued demand for its specialized molecular diagnostic capabilities supporting precision oncology care across the VA system and the broader federal healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 1/22/26 |